Abstract
Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Toll-Like Receptors in Sepsis: A Tale Still Being Told
Volume: 10 Issue: 3
Author(s): Heraldo Possolo Souza, Thais Lima-Salgado and Luis Monteiro da Cruz Neto
Affiliation:
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Abstract: Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Export Options
About this article
Cite this article as:
Possolo Souza Heraldo, Lima-Salgado Thais and Monteiro da Cruz Neto Luis, Toll-Like Receptors in Sepsis: A Tale Still Being Told, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936919
DOI https://dx.doi.org/10.2174/187153010791936919 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design <i>Delonix regia</i> a Folklore Remedy for Diabetes; Attenuates Oxidative Stress and Modulates Type II Diabetes Mellitus
Current Pharmaceutical Biotechnology The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design A Qualitative and Quantitative Study of the Innervation of the Human Non Pregnant Uterus
Current Protein & Peptide Science Identification of Differentially Expressed Hematopoiesis-associated Genes in Term Low Birth Weight Newborns by Systems Genomics Approach
Current Genomics Branched Peptides for the Modulation of Protein-Protein Interactions: More Arms are Better than One?
Current Medicinal Chemistry Regulation of the Steroidogenic Acute Regulatory Protein Expression: Functional and Physiological Consequences
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Identification Osteogenic Signaling Pathways Following Mechanical Stimulation: A Systematic Review
Current Stem Cell Research & Therapy Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Gemini Analogs of Vitamin D
Current Topics in Medicinal Chemistry The Biotransformation of Nitrogen Containing Xenobiotics to Lactams
Current Drug Metabolism Molecularly Imprinted Polymers: Novel Discovery for Drug Delivery
Current Drug Delivery α<sub>IIb</sub>β<sub>3</sub>-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Current Drug Targets Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Antihypertensive Efficacy and Tolerability of Aliskiren/Amlodipine Single- Pill Combinations in Patients with an Inadequate Response to Aliskiren Monotherapy¥
Current Vascular Pharmacology PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry Bone Degeneration, Inflammation and Secondary Complications of Arthritis: Potential Targets and their Natural Inhibitors
Mini-Reviews in Medicinal Chemistry